Open-Label Pilot Trial to Evaluate the Effects of Ilofotase Alfa on Biomarkers in Adult Patients with Hypophosphatasia

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503186-35-00

Acronym

AP-recAP-HPP-01-01

Enrollment

Registered

2023-05-02

Start date

2023-05-03

Completion date

2023-07-12

Last updated

2023-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypophosphatasia

Brief summary

The effect of a low or high dose of ilofotase alfa on the biochemical profile in adult HPP patients.

Interventions

DRUGIlofotase alfa

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The effect of a low or high dose of ilofotase alfa on the biochemical profile in adult HPP patients.	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026